Automate Your Wheel Strategy on RPTX
With Tiblio's Option Bot, you can configure your own wheel strategy including RPTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RPTX
- Rev/Share 1.2517
- Book/Share 2.5723
- PB 0.6589
- Debt/Equity 0.0059
- CurrentRatio 6.3018
- ROIC -1.0493
- MktCap 72815844.0
- FreeCF/Share -2.4076
- PFCF -0.7046
- PE -0.6622
- Debt/Assets 0.005
- DivYield 0
- ROE -0.7825
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates
RPTX
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Negative
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Negative
Repare Therapeutics Inc. (RPTX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.82 per share a year ago.
Read More
About Repare Therapeutics Inc. (RPTX)
- IPO Date 2020-06-19
- Website https://www.reparerx.com
- Industry Biotechnology
- CEO Steve Forte CPA
- Employees 129
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.